HC Wainwright Predicts IN8bio’s Q3 Earnings (NASDAQ:INAB)

IN8bio, Inc. (NASDAQ:INAB) – Stock analysts at HC Wainwright upped their Q3 2026 earnings estimates for IN8bio in a report issued on Friday, August 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.57) for the quarter, up from their prior forecast of ($0.69). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($1.53) per share. HC Wainwright also issued estimates for IN8bio’s Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($1.49) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.34) EPS, Q3 2027 earnings at ($0.35) EPS, Q4 2027 earnings at ($0.22) EPS, FY2027 earnings at ($1.24) EPS, FY2028 earnings at ($0.23) EPS and FY2030 earnings at $0.64 EPS.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.09.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $4.00.

IN8bio Stock Performance

Shares of INAB opened at $0.98 on Tuesday. The stock has a 50 day moving average price of $1.32 and a two-hundred day moving average price of $1.56. The firm has a market capitalization of $9.62 million, a P/E ratio of -0.60 and a beta of 0.24. IN8bio has a 52 week low of $0.90 and a 52 week high of $2.73.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. HRT Financial LP bought a new position in IN8bio in the 4th quarter valued at $34,000. Captrust Financial Advisors bought a new stake in shares of IN8bio during the 4th quarter worth $43,000. Citadel Advisors LLC purchased a new position in shares of IN8bio in the 3rd quarter worth about $54,000. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of IN8bio in the 4th quarter worth about $56,000. Finally, Two Sigma Investments LP bought a new position in IN8bio during the third quarter valued at about $107,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

More IN8bio News

Here are the key news stories impacting IN8bio this week:

• Positive Sentiment: HC Wainwright reduced its projected FY2026 loss to $1.49 per share from $2.10 and its FY2027 loss to $1.24 per share from $1.51. Quarterly estimates were also improved, including Q3 2026 to ($0.57) from ($0.69) and Q4 2026 to ($0.65) from ($0.77).
• Positive Sentiment: The analyst raised its FY2028 forecast to a loss of $0.23 per share from $0.44, signaling a potentially faster path toward profitability. HC Wainwright continues to project positive earnings of $0.64 per share in FY2030.
• Positive Sentiment: The revisions are more optimistic than the current consensus forecast of a $1.53-per-share loss for the year, which may improve investor sentiment toward IN8bio’s financial outlook.
• Neutral Sentiment: HC Wainwright also issued a FY2029 earnings forecast, but the supplied report does not provide the estimate. FY2029 Earnings Forecast for IN8bio Issued By HC Wainwright
• Negative Sentiment: Despite the upgrades, IN8bio is still expected to report substantial losses through FY2028, and HC Wainwright slightly lowered its FY2030 earnings estimate to $0.64 from $0.69.
• Negative Sentiment: Shares remain near the one-year low and below their 50-day and 200-day moving averages, indicating continued technical weakness. The company also has a small market capitalization of approximately $9.6 million, which can contribute to heightened volatility and financing risk.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.